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Klebsiella pneumoniae is an important cause of urinary tract infection (UTI), but little is known about its
pathogenesis in vivo. The pathogenesis of the K. pneumoniae cystitis isolate TOP52 was compared to that of the
uropathogenicEscherichia coli (UPEC) isolate UTI89 in amurine cystitis model. Bladder and kidney titers of TOP52
were lower than those of UTI89 at early time points but similar at later time points. TOP52, like UTI89, formed
biofilm-like intracellular bacterial communities (IBCs) within themurine bladder, albeit at significantly lower levels
than UTI89. Additionally, filamentation of TOP52 was observed, a process critical for UTI89 evasion of neutrophil
phagocytosis and persistence in the bladder. Thus, the IBC pathway is not specific to UPEC alone. We investigated
if differences in type 1 pilus expression may explain TOP52’s early defect in vivo. The type 1 pilus operon is
controlled by recombinase-mediated (fimE, fimB, and fimX) phase variation of an invertible promoter element. We
found that K. pneumoniae carries an extra gene of unknown function at the 3 end of its type 1 operon, fimK, and the
genome lacks the recombinase fimX. A deletion mutant of fimK was constructed, and TOP52fimK had higher titers
and formed more IBCs in the murine cystitis model than wild type. The loss of fimK or expression of E. coli fimX
from a plasmid in TOP52 resulted in a larger phase-ON population and higher expression levels of type 1 pili and
gave TOP52 the ability to form type 1-dependent biofilms. Complementation with pfimK decreased type 1 pilus
expression and biofilm formation of TOP52 fimK and decreased UTI89 biofilm formation. Thus, K. pneumoniae
appears programmed for minimal expression of type 1 pili, which may explain, in part, why K. pneumoniae is a less
prevalent etiologic agent of UTI than UPEC.
Nearly 13 million women get urinary tract infections (UTIs)
per year in the United States alone, and more than half of all
women will experience a UTI during their lifetimes (16, 23, 28, 29,
52). These infections often recur, and over half of all recurrent
episodes are caused by the same bacterial strain as the initial
infection (17, 54). Uropathogenic Escherichia coli (UPEC) is the
most common etiologic agent, responsible for 80 to 85% of com-
munity-acquired UTIs (51). However, there are several other
significant uropathogens; including Staphylococcus saprophyticus,
Klebsiella pneumoniae, and Proteus mirabilis (49).
K. pneumoniae causes up to 5% of community-acquired
UTIs and is significantly more common in diabetic patients and
in the nosocomial setting (26, 36, 50). The urinary tract is the
most common site of Klebsiella infection, although it may be
better recognized as a cause of pneumonia in compromised
hosts (7). Over the past 25 years, there has been a substantial
increase in the spread of drug-resistant strains of Klebsiella,
particularly those producing extended-spectrum -lactamases
(42). K. pneumoniae encodes type 1 pili, and its corresponding
fim operon is highly homologous to that of E. coli (14, 22). As
with E. coli, expression of the fim operon is phase variable,
controlled by an invertible promoter element, fimS. fimE and
fimB are recombinase genes in the type 1 pilus gene cluster
that mediates the phase switching of fimS (33). fimX is not part
of the fim gene cluster but encodes a recombinase that is also
important in fimS phase switching in vivo (4, 25). ON-phase K.
pneumoniae displays superior in vitro binding to ciliated ham-
ster tracheal epithelial cells and rat bladder epithelial cells (12,
15) and in vivo infection of the rat urinary tract (13) compared
to OFF-phase organisms. It has also been shown that infection
of the mouse urinary tract leads to a population shift favoring
organisms expressing type 1 pili (37).
UPEC strains utilize a multistep pathogenic pathway during
human and murine infection in which the bacteria invade bladder
facet cells and replicate intracellularly (1, 19, 30, 44, 53). Almost
all UPEC strains express type 1 pili, which consist of thin-tipped
fibrillae attached to thicker pilus rods (5). Genes essential for
UPEC type 1 pilus biogenesis are organized in the fim operon,
with fimH encoding the adhesin that recognizes mannosylated
uroplakins on the luminal surface of facet cells (63). Binding of
UPEC to the host cell, possibly through 1 and 3 integrins,
induces a cascade of signaling events that leads to bacterial inter-
nalization (11, 38, 39). Within the superficial facet cells of the
bladder, piliated UPEC bacteria replicate to form intracellular
bacterial communities (IBCs) with biofilm-like properties (1, 62).
IBCs are transient, and the bacteria ultimately flux out of epithe-
lial cells, some adopting a filamentous morphology. These long
filaments evade engulfment by neutrophils and are necessary for
persistence in the murine cystitis model (31). UPEC is also able to
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form quiescent intracellular reservoirs (QIRs) that can persist for
several weeks protected from antibiotics and seemingly undetec-
ted by the host immune system (44, 46, 57). It has not yet been
determined whether non-UPEC uropathogens, such as K. pneu-
moniae, utilize an intracellular bladder niche during infection. In
this study we investigated the pathogenesis of K. pneumoniae in
the murine cystitis model compared to UPEC. We discovered
interesting differences in the pathogenic pathway of K. pneu-
moniae that were related to the expression of type 1 pili.
MATERIALS AND METHODS
Bacterial strains and culture conditions. A complete list of bacterial strains
and plasmids used in this study can be found in Table 1. Clinical strains used
include UTI89, a UPEC cystitis isolate (44), and TOP52 1721 (abbreviated
TOP52), a K. pneumoniae cystitis isolate. TOP52 was isolated from the urine of
a 26-year-old woman with acute cystitis from a previous UTI study (53). After
successful completion of antibiotic therapy and negative follow-up urine cultures,
this patient developed recurrent cystitis with the same strain of K. pneumoniae,
as determined by restriction fragment length polymorphism analysis. Bacteria
were cultured at 37°C in Luria-Bertani (LB) broth containing, as appropriate, 20
g/ml chloramphenicol, 50 g/ml kanamycin, and arabinose as indicated below.
TOP52 and UTI89 mutant construction and complementation. Targeted de-
letion mutants of fimK and fimA-fimH in the K. pneumoniae isolate TOP52 were
constructed with the pKOV vector as described previously (35). Flanking se-
quences of approximately 1,000 bp on each side of the targeted gene were
amplified with the primers indicated in Table 2 and cloned into pKOV. Potential
knockouts were screened by PCR, and the knockout region was sequenced.
Growth curves were done for all mutant strains and showed no differences in
growth compared to the wild type.
UTI89 fimA-fimH was constructed using the red recombinase method as
previously described (9, 45), with pKD4 as a template and the primers indicated
in Table 2. PCR using flanking primers was used to confirm the deletion.
For complementation studies, fimK was amplified and cloned into the arabi-
nose-inducible pBAD33 vector (abbreviated pBAD) to make pfimK. TOP52
fimK was sequenced using both amplification primers and pBAD plasmid prim-
ers. Homology searches were conducted using BLASTN and BLASTP to look
for homologous genes, proteins, and domains. For expression of fimX, the pfimX
vector, which contains fimX of UTI89 cloned into pBAD, was used as previously
described (25).
Mouse infections. Bacterial strains were used to inoculate 8-week-old female
C3H/HeN mice (National Cancer Institute) by transurethral catheterization as
previously described (43). Static cultures (25 ml) were started from freezer stocks
and grown at 37°C for 18 h and then subcultured at 1:250 into 25 ml of fresh
medium. These cultures were then grown statically at 37°C for 18 h and centri-
fuged for 5 min at 5,800 rpm, and the resultant pellet was resuspended in
phosphate-buffered saline (PBS) and diluted to approximately 2  108 CFU/ml.
Fifty milliliters of this suspension was used to infect each mouse with an inocu-
lum of 1 107 to 2 107 CFU. All studies were approved by the Animal Studies
Committee at Washington University School of Medicine.
Urine collection. For mouse urine studies, samples were collected 24 h post-
inoculation by bladder massage over a sterile 1.5-ml Eppendorf tube and cyto-
centrifuged for 6 min at 1,000 rpm onto poly-L-lysine-coated glass slides using a
CytoPro 7620 cytocentrifuge (Wescor). Slides were stained with filter-sterilized
Protocol Hema 3 stains (Wright-Giemsa method; Fisher Scientific) and analyzed
by light microscopy using an Olympus BX51 light microscope (Olympus
America).
TABLE 1. Bacterial strains and plasmids
Strain or plasmid Description Reference orsource
Strains
UTI89 UPEC cystitis isolate 44
UTI89 fimA-fimH Knockout of fimA-fimH in
UTI89
This study
TOP52 1721 K. pneumoniae cystitis isolate 53; also this
study
TOP52 fimK Knockout of fimK in TOP52 This study




pBAD33 Empty expression vector;
arabinose inducible; Cmr
24




pfimX UTI89 fimX expression vector;
arabinose inducible; Cmr
25
TABLE 2. Primer sequences
Primer name Primer use Primer sequence
NotIFimKF1 Amplify 1-kb fimK 5 flanking region 5-CGGTAACGCGGCCGCGACTATCCGGAAACGATCACC-3
HindIIIFimKR2 Amplify 1-kb fimK 5 flanking region 5-AACAAGCTTAGACGATCCGGATGACTCAC-3
HindIIIFimKF3 Amplify 1-kb fimK 3 flanking region 5-CATAAGCTTAGAAAAGCGCACCGGTTA-3
SalIFimKR4 Amplify 1-kb fimK 3 flanking region 5-AACGTCGACAAAACAGAAACCACAGCAACG-3
3FimKCheckF Check TOP52 fimK 5-GTCGATTATCGGCATCACCT-3
3FimKCheckR Check TOP52 fimK 5-GTGGCGAAGGTAGTGGAAAA-3
NotIFimF1 Amplify 1-kb fimA 5 flanking region 5-CGGTAACGCGGCCGCGCATTAGCGAACTGCTGGAT-3
BamHIFimR2 Amplify 1-kb fimA 5 flanking region 5-AACGGATCCCAGGGCTGACACAACAATCA-3
BamHIFimF3 Amplify 1-kb fimH 3 flanking region 5-TACGGATCCGTCAATCTCGGCCTGACG-3
SalIFimR4 Amplify 1-kb fimH 3 flanking region 5-AACGTCGACGGAGGGTATGTTGACCGAAA-3
3FimCheckF Check TOP52 fimA-fimH 5-CCAACGCCATCGCTATTC-3
3FimCheckR Check TOP52 fimA-fimH 5-GATACACCACGATCCGCTTC-3
3FimKcompF Amplify TOP52 fimK for cloning into pBAD 5-AAT TCC ATG GGGCATCACCTTTGTCTATCAATGATG-3
3FimKcompR Amplify TOP52 fimK for cloning into pBAD 5-AATTGGTACCCGGTGCGCTTTTCTCGCACCCTCAACG-3
pBADF Check pBAD clones 5-TATCGCAACTCTCTACTGTTTCTCCA-3
pBADR Check pBAD clones 5-CTGTATCAGGCTGAAAATCTTCTCTCA-3
UTI89fimA-H KO F Knockout fimA-fimH in UTI89 5-ATGAAAATTAAAACTCTGGCAATTGTTGTTCTGTCGGCT
CTGTCCCTGAGCATATGAATATCCTCCTTAG-3
UTI89fimA-H KO R Knockout fimA-fimH in UTI89 5-TTATTGATAAACAAAAGTCACGCCAATAATCGATTG CA
CATTCCCTGCAGGTGTAGGCTGGAGCTGCTTC-3
UTI89fimA-HcheckF Check UTI89 fimA-fimH 5-GTTTGTGCGCGATGCTTTCC-3
UTI89fimA-HcheckR Check UTI89 fimA-fimH 5-GAGCACCTGAGCCTGCCATT-3
2KlebphaseF Amplify fimS region for phase assay 5-GGGACAGATACGCGTTTGAT-3
2KlebphaseR Amplify fimS region for phase assay 5-GGGACAGATACGCGTTTGAT-3
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Organ titers, gentamicin protection assays, and IBC enumeration. To quantify
bacteria present in mouse organs, bladders and kidneys were aseptically har-
vested at the indicated times postinfection, homogenized in PBS, serially diluted,
and plated onto LB agar plates. Luminal and intracellular bacteria were quan-
tified using an ex vivo gentamicin protection assay as previously described (32).
For ex vivo enumeration of IBCs, infected bladders were harvested at the times
indicated in the figure legends, bisected, splayed, washed with PBS, fixed with 3%
paraformaldehyde for 60 min at room temperature, and lacZ stained as previ-
ously described (32). IBCs were visualized and counted using an Olympus SZX12
dissecting microscope (Olympus America).
Histology and immunohistochemistry. Infected mouse bladders were asepti-
cally removed, fixed in neutral buffer formalin, and paraffin embedded, and
sections were stained with hematoxylin and eosin. For immunohistochemistry,
unstained slides were deparaffinized, washed in filter-sterilized PBS, blocked in
1% bovine serum albumin–0.3% Triton X-100 for 1 h at room temperature, and
subsequently incubated for 1 h with rabbit anti-E. coli (1:1,000; U.S. Biological),
rabbit anti-K. pneumoniae (1:100; Virostat), or rabbit anti-gel-purified type 1 pili
(1:500) (48) and goat anti-uroplakin III (1:100; Santa Cruz Biotechnology) pri-
mary antibodies. After three washes in PBS for 5 min and staining with Alexa
Fluor 488- and 594-conjugated donkey secondary antibodies (1:1,000; Molecular
Probes) for 30 min, slides were washed, stained with Hoechst, coverslipped with
Fluoromount G (Southern Biotechnology Assoc.), and examined using an epi-
fluorescent Zeiss Axioskop instrument (Carl Zeiss).
FimA immunoblotting, phase assays of the fim operon switch, and antigenic
titration assays. For immunoblot analysis bacterial strains were grown statically as
described above for mouse infections with 0.01% arabinose, as appropriate. Acid-
treated whole-cell immunoblotting was performed as previously described (19) using
1:2,000 rabbit anti-type 1 pilus primary antibody (48). Bacteria were normalized by
optical densities at 600 nm (OD600), and Coomassie blue staining was performed to
verify similar levels of protein in each lane. The intensity of each band was analyzed
using ImageJ software (http://rsb.info.nih.gov/ij/).
To determine the orientation of the fimS phase switch in TOP52, a phase assay
was adapted from the E. coli assay previously described (59). PCR primers were
used to amplify an 815-bp DNA region including fimS. The PCR product was
then digested with the restriction endonuclease Hinf1 (New England Biolabs)
and run on a 2.5% agarose gel. A phase-ON switch results in products of
approximately 495 and 320 bp, and a phase-OFF switch results in products of
approximately 600 and 215 bp.
For antigenic titration assays, all strains were grown statically at 37°C in LB
with appropriate antibiotics and 0.1% arabinose, as indicated in Table 3. Sero-
logical titers using monospecific antiserum to type 1 pili or type 3 pili (20, 21)
required to agglutinate strains were determined as previously described (10).
Negative-stain EM. Strains were cultured as described above for mouse infec-
tions and were prepared for electron microscopy (EM) as follows. Bacteria were
absorbed onto Formvar-carbon-coated copper grids for 1 min. Grids were
washed in distilled water and stained with 1% aqueous uranyl acetate (Ted Pella
Inc.) for 1 min. Excess liquid was gently wicked off, and grids were allowed to air
dry. Samples were viewed on a JEOL 1200EX transmission EM (JEOL USA) at
an accelerating voltage of 80 kV, and representative images are shown.
Biofilm assays. Bacteria were grown in LB broth in wells of microtiter plates
in the presence of 0.1% arabinose (for complementation in UTI89) or 0.01%
arabinose (for complementation in TOP52), as appropriate. After 48 h of growth
at room temperature, wells were rinsed and stained with crystal violet, and
biofilms were quantified as previously described (47). Resulting graphs compare
means  standard errors of the means of two independent experiments, each
with duplicate plates.
Statistical analysis. Continuous variables were compared using a Mann-Whit-
ney U test since these variables were not normally distributed. For biofilm data,
means of multiple plates from two independent experiments were compared, and
t tests were performed. All tests were two tailed, and a P value less than 0.05 was
considered significant. Analyses were performed using GraphPad Prism (version
4.03; GraphPad Software).
Nucleotide sequence accession number. The TOP52 fimK nucleotide sequence
has been deposited in the GenBank database under accession number EU315065.
RESULTS
TOP52 compared to UTI89 in a murine cystitis model. To
contrast urinary tract infections of K. pneumoniae and E. coli,
C3H/HeN female mice were inoculated by transurethral cath-
eterization with 107 CFU of TOP52, a K. pneumoniae cystitis
isolate, or 107 CFU of UTI89, an E. coli cystitis isolate. Inoc-
ulations with less than 107 CFU of TOP52 did not result in
consistent infection in the mouse model (data not shown).
FIG. 1. Time course of TOP52 and UTI89 bladder and kidney infections and gentamicin protection assays. Female C3H/HeN mice were
inoculated with 107 CFU of TOP52 or UTI89 by transurethral inoculation. For organ titers, bladders (A) and kidneys (B) were harvested at various
time points postinfection, and the numbers of CFU were calculated. Titer data are combined from three independent experiments. For ex vivo
gentamicin protection assays, bladders were harvested at 6 h (C) and 24 h (D) postinfection, and luminal and intracellular populations of bacteria
were quantified. Short bars represent geometric means of each group, and dotted lines represent limits of detection. Significant P values, as
calculated using the Mann-Whitney U test, are shown on the figure.
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Bladders and kidneys were harvested at various time points
postinoculation, and bacterial titers were determined. In the
bladder (Fig. 1A), TOP52 had significantly lower titers than
UTI89 at both the 6-h (P	 0.0001) and 24-h (P
 0.0487) time
points. At later time points, TOP52 and UTI89 titers were
similar in bladders. At 2 weeks postinoculation, the distribu-
tions of TOP52 and UTI89 titers were similar in bladders. In
the kidney (Fig. 1B), TOP52 had slightly lower titers than
UTI89 at 6 h (P 
 0.0304); however, it had similar or higher
titers than UTI89 in the kidney at all other time points tested.
It has been shown that UPEC bacteria invade bladder epi-
thelial cells during infection. The ability of K. pneumoniae to
invade bladder epithelial cells during UTI was investigated
using gentamicin protection assays of the bladder performed at
6 h and 24 h postinoculation. At each time point, luminal
bacteria were collected by successive bladder washes prior to
gentamicin treatment. TOP52, like UTI89, had substantial in-
tracellular populations of bacteria at both 6 and 24 h postin-
oculation. At 6 h (Fig. 1C), TOP52 had significantly more
intracellular bacteria than luminal bacteria (P
 0.0087), as did
UTI89 (P 
 0.0022). By 24 h (Fig. 1D), the number of intra-
cellular bacteria was similar to the number of extracellular
bacteria for both TOP52 and UTI89. However, the numbers of
both luminal and intracellular TOP52 bacteria were signifi-
cantly lower than the respective UTI89 levels at 6 h (P 

0.0022). Thus, TOP52 may be defective in adherence and/or
invasion of the bladder urothelium early in infection relative to
UTI89.
These data demonstrate that the K. pneumoniae cystitis iso-
late TOP52 is able to infect the bladder and kidneys of mice in
the murine cystitis model. However, TOP52 has significantly
reduced titers early in infection compared to the E. coli cystitis
isolate, UTI89. Similar to UTI89, there also appears to be a
significant intracellular population of TOP52 early in infection.
TOP52 progresses through an IBC pathway. Histology was
performed on TOP52 bladders at 6 h postinoculation, and
numerous sections were analyzed in order to further charac-
terize the intracellular population of TOP52. Large IBCs were
found in TOP52-infected bladders (Fig. 2A). These biofilm-
like communities, found within superficial bladder facet cells,
appeared morphologically identical to those found in UTI89-
infected bladders (Fig. 2B). Immunohistochemistry staining
with Klesbsiella-specific antibodies confirmed that these IBCs
were composed of K. pneumoniae (data not shown). Staining
with antibodies against type 1 pili confirmed that type 1 pili are
expressed within TOP52 IBCs and UTI89 IBCs (green areas in
Fig. 2C and D, respectively), similar to what has been reported
previously for UTI89 (62). At 24 h postinoculation, filamen-
tous bacteria, another hallmark of the IBC pathway, were
found in urine samples from both TOP52-infected (Fig. 2E)
and UTI89-infected (Fig. 2F) mice.
IBCs were visualized and quantified by lacZ staining of
whole mounted, fixed bladders at 6 and 24 h postinoculation of
TOP52 or UTI89 (Fig. 2G). TOP52 had significantly fewer
IBCs than UTI89 at both the 6-h (P 
 0.0012) and 24-h (P 

0.0221) time points. Taken together, these data demonstrate
that TOP52 progresses through an IBC pathogenic pathway.
TOP52, however, forms fewer IBCs than UTI89 early in
infection.
The fim operon of TOP52 contains fimK, and TOP52 fimK
has higher bacterial titers in vivo. We investigated whether the
differences in bacterial burden and IBC formation between
TOP52 and UTI89 observed at early time points in infection
may, in part, relate to the expression of type 1 pili. We found
FIG. 2. TOP52 progresses through an IBC pathogenic pathway. Histologic analysis of murine bladders after a 6-h infection with TOP52 (A) or
UTI89 (B) revealed morphologically identical IBCs within superficial urothelial cells. Immunohistochemistry demonstrated that bacteria express
type 1 pili within IBCs of both TOP52 (C) and UTI89 (D) infections. Staining was done with antibodies against type 1 pili (green) and the facet
cell marker uroplakin III (red), and nuclei were visualized with Hoescht staining (blue). Urine samples from mice at 24 h postinfection with TOP52
(E) or UTI89 (F) contained long bacterial filaments. IBCs were quantified after visualization by LacZ staining and revealed that TOP52 forms
significantly fewer IBCs than UTI89 at both 6 and 24 h postinoculation (G). Short bars represent geometric means, and significant P values, as
calculated using the Mann-Whitney U test, are shown on the figure. Scale bar, 10 m (A to F).
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that while K. pneumoniae encodes intact fimB and fimE recom-
binases important in mediating phase variation of the invert-
ible promoter element, it lacks fimX. Compared to UTI89, the
fim operon of TOP52 also contains an extra gene of unknown
function, fimK (Fig. 3A). fimK was also found to be present
immediately downstream of fimH in both of the other strains of
K. pneumoniae for which the sequence of this region was avail-
able (22, 41). The sequence of the 1,410-bp open reading frame
of fimK (GenBank accession number EU315065) showed no
homology to sequenced bacterial genes. However, the carboxy-
terminus contained an EAL domain, a domain which has pre-
viously been implicated in cleavage of the second messenger
cyclic-di-GMP (8, 58, 60).
A deletion mutant of fimK was constructed, and the ability
of TOP52 fimK to colonize and form IBCs was investigated in
the murine cystitis model. At 6 h postinoculation, TOP52
fimK had significantly higher titers in bladder (Fig. 3B) and
kidney (Fig. 3C) than wild-type TOP52 (P 
 0.0112 and P 

0.0240, respectively). The fimK gene was cloned downstream of
an arabinose-inducible promoter to make pfimK for comple-
mentation studies. TOP52 fimK/pfimK had significantly lower
titers in bladder and kidney than the empty vector control,
TOP52 fimK/pBAD (P 
 0.0006 and P 
 0.0091, respec-
tively).
lacZ staining of whole mounted, fixed bladders was per-
formed to determine if the deletion of fimK had a quantitative
effect on IBC formation (Fig. 3D). While wild-type TOP52
formed a mean of 1.8 IBCs per bladder, TOP52 fimK formed
4.6 (P 
 0.0312). The TOP52 fimK/pBAD vector control
formed a mean of 5.7 IBCs per bladder while TOP52 fimK/
pfimK formed 3.3 IBCs per bladder (P 
 0.0939). These data
suggest that loss of fimK results in higher bacterial titers,
greater numbers of IBCs, and overall more-efficient bladder
infection.
TOP52 fimK and TOP52/pfimX have higher expression lev-
els of type 1 pili. We hypothesized that the low bladder colo-
nization and IBC formation levels of TOP52 compared to
UTI89 may be related to type 1 pilus expression. Possible
differences in type 1 pilus expression could potentially result
from the lack of the fimX recombinase or the presence of the
fimK gene in TOP52. The higher titers in bladder and in-
creased abundance of IBCs observed with the loss of fimK
could potentially be explained by a higher level of type 1 pilus
expression. Thus, the effects of fimK loss or fimX addition on
type 1 pilus expression were investigated. Levels of the major
type 1 pilus subunit, FimA, were monitored by whole-cell im-
munoblotting using anti-FimA antibodies. Cells were normal-
ized by OD600, and Coomassie staining was used to verify
similar levels of protein in each lane. In addition, the orienta-
tion of the fimS promoter was analyzed in phase assays to test
if the loss of fimK or the addition of fimX affects type 1 pilus
expression (Fig. 4). TOP52 fimK produced a larger FimA
band than TOP52 as determined by immunoblot analysis.
Complementation of TOP52 fimK with pfimK reduced the
size of the FimA band to close to the wild-type level. More-
over, the addition of fimX in TOP52 also led to the production
of a larger FimA band than that produced by the vector con-
trol. As a control, fimA-fimH was deleted in TOP52. This
negative-control strain, TOP52 fimA-fimH, did not produce a
FimA band.
Phase assays were performed in which the fimS invertible
region was amplified by PCR and digested using a restriction
endonuclease to determine the orientation of the fim operon
promoter. TOP52 fimK had a larger proportion of phase-ON
FIG. 3. TOP52 fimK has higher titers in organs and forms more IBCs
in the murine cystitis model than the wild type. (A) The fim operons ofE. coli
and K. pneumoniae, which encode type 1 pili, have similar compositions and
organizations, but the K. pneumoniae fim operon contains an extra gene of
unknown function, fimK. (B) TOP52 fimK had higher 6-h titers in the
bladder than the wild type, and this phenotype was complemented with
pfimK. (C) TOP52 fimK also had consistently higher titers in the kidney at
6 h than the wild type, and this difference could be complemented back to
wild-type levels. (D) Enumeration of IBCs at 6 h postinfection revealed that
TOP52 fimK forms more IBCs than TOP52. Titer and IBC data are com-
bined from three independent experiments. Short bars represent geometric
means of each group, and dotted lines represent limits of detection. Signifi-
cant P values, as calculated using the Mann-Whitney U test, are shown in the
figure.
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cells than TOP52, which was primarily phase OFF. This
phenotype could be partially complemented using pfimK.
TOP52 fimK/pfimK had a slightly larger phase-OFF popula-
tion than the TOP52 fimK/pBAD vector control. Expression
of fimX in TOP52 resulted in a significant shift in the popula-
tion to the phase-ON position compared to the TOP52/pBAD
vector control, which was primarily phase OFF. The negative
control, TOP52 fimA-fimH, did not yield a PCR product
because a portion of the corresponding DNA had been de-
leted.
For semiquantitative measures of type 1 pilus expression in
these K. pneumoniae strains, we performed antigenic titration
assays (Table 3). This assay tests the ability of various dilutions
of type 1 pilus-monospecific antiserum to agglutinate bacteria.
For wild-type TOP52, only dilutions of antibody up to 1:160
caused agglutination, while TOP52 fimK agglutinated at lev-
els up to 1:2,560, indicating much higher expression of type 1
pili in TOP52 fimK. While the vector control resulted in
similar antibody titers, complementation of TOP52 fimK with
pfimK resulted in a titer of 1:80 with arabinose induction, thus
fully decreasing type 1 piliation down to levels similar to wild
type. The negative control TOP52 fimA-fimH, as expected,
did not agglutinate even with the highest concentration of type
1 antiserum. It should also be noted that all strains had similar
titers when antiserum to type 3 pili was used (data not shown),
indicating that fimK does not affect expression of type 3 pili.
Additionally, negative-stain EM was performed to visualize
type 1 pili in the different strains (Fig. 5). Wild-type TOP52
showed low to moderate levels of type 1 piliation, while TOP52
fimA-fimH was exclusively bald. TOP52 fimK and TOP52
fimK/pBAD had a dramatic shift in the proportion of heavily
type 1-piliated bacteria. This hyperpiliation phenotype was re-
duced in TOP52 fimK/pfimK. TOP52/pfimX also displayed
higher levels of piliation than the TOP52/pBAD vector control.
These data suggest that fimK inhibits type 1 piliation in
TOP52 and that the addition of fimX can increase piliation.
This was demonstrated at the transcriptional level in which loss
of fimK or the addition of fimX resulted in an increased pop-
ulation of phase-ON bacteria and increased amounts of FimA.
Wild-type TOP52 was primarily phase OFF, with inherently
low production of type 1 pili possibly hindering its ability to
cause infection in the urinary tract. The presence of fimK and
lack of fimX in TOP52 may, in part, account for the signifi-
cantly reduced bacterial titers early in infection compared to
those in UTI89.
fimK and fimX affect in vitro biofilm formation. To deter-
mine if the loss of fimK or the gain of fimX has effects on type
1-dependent biofilm formation, which may be important in
vivo, TOP52 biofilm assays were performed (Fig. 6A). Crystal
violet was used to stain biofilms, and the amount of biofilm was
quantified by measuring absorbance at OD600. Wild-type
TOP52 failed to make biofilm in this assay after 48 h as did the
negative control, TOP52 fimA-fimH. TOP52 fimK, however,
formed biofilm under the same conditions. TOP52 fimK/
pfimK made significantly less biofilm than the TOP52 fimK/
pBAD vector control (P 
 0.0128). Thus, complementation of
TOP52 fimK with pfimK significantly reduced its ability to
form biofilm. Expression of the recombinase fimX on a plasmid
also conferred TOP52 with the ability to form biofilm. TOP52/
pfimX made significantly more biofilm than the TOP52/pBAD
vector control, which was unable to form biofilm (P 
 0.0002).
TOP52 fimA-fimH/pfimX did not form biofilm (data not
shown), verifying that biofilm formation required type 1 pilus
expression.
UTI89 was transformed with pfimK in order to determine if
fimK expression would also reduce UTI89 biofilm formation
(Fig. 6B). Wild-type UTI89 formed a robust biofilm after 48 h.
The negative control, UTI89 fimA-fimH, was unable to form
biofilm. Expression of pfimK in UTI89 decreased biofilm for-
mation compared to that of the UTI89/pBAD vector control
(P 
 0.0022).
While wild-type TOP52 is unable to form type 1 pilus-de-
pendent biofilms, loss of fimK or addition of fimX transforms a
non-biofilm former into a biofilm producer. Interestingly, these
FIG. 4. TOP52 fimK and TOP52/pfimX have higher expression
levels of type 1 pili than wild type and vector controls. FimA immu-
noblot analysis showed that TOP52 fimK makes more type 1 pili than
wild-type TOP52. Expression of FimA was complemented down to
wild-type levels with pfimK. TOP52/pfimX also produced a much larger
FimA band than the vector control. Bacteria were normalized by
OD600, and Coomassie blue staining was used to verify similar levels of
protein in each lane. Relative densitometry was calculated using Im-
ageJ software. Phase assays, showing the orientation of the fimS pro-
moter region of the fim operon, revealed that the wild-type TOP52 and
TOP52/pBAD vector control were largely phase OFF while TOP52
fimK and TOP52/pfimX had significant phase-ON populations.
TABLE 3. Serological titers required to agglutinate K. pneumoniae
strains using monospecific antiserum to type 1 pili
Strain Growth witharabinose Titer
a
TOP52  160
TOP52 fimK  2,560
TOP52 fimK/pBAD  1,280
TOP52 fimK/pBAD  2,560
TOP52 fimK/pfimK  1,280
TOP52 fimK/pfimK  80
TOP52 fimA-fimH  	20b
a Titers are the reciprocal of the highest dilution of serum causing visible
agglutination after 5 min. Titers represent the median of three independent
experiments.
b The lowest dilution of antibody used in this assay was 1:20.
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data suggest that fimK acts as an inhibitory factor for biofilm
formation in both TOP52 and UTI89, likely by affecting
changes in expression of type 1 pili. Thus, fimK likely affects
type 1 pili or biofilm regulatory pathways that are conserved in
both K. pneumoniae and E. coli.
DISCUSSION
Even though K. pneumoniae is the second most common
cause of gram-negative UTI, few studies have analyzed the
pathogenesis of K. pneumoniae in a UTI model. In this study,
we infected mice with TOP52, a K. pneumoniae cystitis isolate,
and found that, early in infection, it had lower titers than
UTI89, a UPEC strain, in bladder and kidney. The reason for
this early deficiency is likely related, in part, to the type 1
piliation state of TOP52.
TOP52 carries the gene fimK, which acts to reduce type 1
piliation. Additionally, TOP52 lacks fimX, a recombinase gene
able to increase type 1 piliation. These factors may predispose
K. pneumoniae to be a less-effective uropathogen than UPEC.
The few bacteria that get introduced into the host bladder (3,
6, 27) are less likely to adhere to or invade the bladder surface
because of less type 1 piliation. A less-piliated organism is
presumably at a significant disadvantage upon entrance into
the bladder and is less likely to survive to initiate significant
infection in the host. In addition, it should be noted that while
we analyzed the expression of K. pneumoniae type 1 pili, it is
not clear that their function is the same as that of E. coli type
1 pili. More work needs to be done to determine if there are
structural or functional differences between K. pneumoniae
and UPEC type 1 pili that may also affect UTI pathogenesis.
TOP52 was able to form biofilm-like IBCs in the bladder;
however, it made significantly fewer IBCs than UTI89. Inter-
estingly, despite this defect, TOP52 titers are similar to those
of UTI89 at later time points in infection. TOP52 may be able
to persist at a relatively constant level throughout the course of
infection while UTI89 infection levels decrease to the level of
TOP52. This could be due to the influence of the host inflam-
matory responses to each uropathogen. Alternatively, there
may be a lag in K. pneumoniae infection due to type 1 pilus
FIG. 5. TOP52 fimK and TOP52/pfimX appear hyperpiliated by negative-stain EM. Negative-stain EM was performed on TOP52 cultures,
and representative images are displayed. TOP52 had low to moderate piliation, and the negative control TOP52 fimA-fimH appeared bald.
TOP52 fimK was hyperpiliated compared to the wild type, and this phenotype could be partially complemented with pfimK. TOP52/pfimX also
displayed higher levels of piliation than the vector control.
FIG. 6. The presence of fimK and fimX affects biofilm formation
of TOP52 and UTI89. A 48-h biofilm assay was used to quantify
biofilms produced by TOP52 strains (A) and UTI89 strains (B).
TOP52 and the negative control TOP52 fimA-fimH failed to form
biofilms. However, TOP52 fimK and TOP52/pfimX were able to
form biofilms. TOP52 fimK/pfimK formed significantly less biofilm
than the vector control. Wild-type UTI89 formed a robust biofilm,
and the negative control UTI89 fimA-fimH was unable to form a
biofilm. Complementation of UTI89 with TOP52 fimK resulted in
significantly less biofilm formation than that produced by the
UTI89/pBAD vector control. Data combine means of two indepen-
dent experiments, each with duplicate plates. Error bars represent
standard errors of the means.
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expression or other factors. Bacterial filamentation has been
shown to be important for UPEC persistence in the murine
cystitis model (31). It should be noted that no obvious differ-
ences in the levels of bacterial filamentation were observed in
24-h urine samples of UTI89-infected and TOP52-infected
mice; however, quantitative measurements of filamentation
were not performed. Ultimately, both UTI89 and TOP52 were
able to effectively persist in similar ways in the murine cystitis
model with an inoculum of 107 CFU. In humans, relatively few
bacteria are introduced into the bladder, and if K. pneumoniae
has a lower probability of forming IBCs than UPEC, then K.
pneumoniae may be cleared more efficiently.
This is the first account of a non-UPEC uropathogen form-
ing IBCs in the bladder. Thus, the ability to form IBCs is not
specific to UPEC. The IBC pathway may be a conserved mech-
anism by which many uropathogens evade the host innate
immune response. Uropathogens may form these intracellular
biofilms to multiply unhindered within the protected niche of
the urothelial cell and even escape antibiotic penetration. Fur-
ther studies need to be done to determine which uropathogens,
including other K. pneumoniae isolates, are able to utilize an
intracellular niche during acute bladder infection.
UPEC IBCs are transient in nature; however, UPEC has the
ability to form long-lasting QIRs that can seed recurrent in-
fection (46). These QIRs consist of bacterial rosettes within
Lamp-1-positive endocytic vesicles. This study did not analyze
long-term reservoir formation by K. pneumoniae. Future stud-
ies are needed to determine if K. pneumoniae can form QIRs
and if these reservoirs can seed recurrent infection.
While it is clear that the presence of FimK inhibits type 1
piliation in K. pneumoniae, the mechanism of this inhibition is
not known. FimK does contain an EAL domain, named after
conserved residues, which has been implicated in the cleavage
of the second messenger molecule, cyclic di-GMP (8, 58, 60).
Loss of FimK may lead to higher levels of cyclic di-GMP, which
has been implicated in biofilm formation, production of adhe-
sive surface structures, and inhibition of motility (18, 34, 61).
Further studies are needed to determine if FimK is an active
phosphodiesterase with the ability to cleave cyclic di-GMP and
how this second messenger may influence expression of type 1
pili in K. pneumoniae. FimK may be acting exclusively on the
expression of type 1 pili, or FimK may also affect the expres-
sion of other adhesins or virulence factors in K. pneumoniae
that may play a role in UTI. The ability of FimK to decrease
type 1 pilus-dependent biofilm formation in UTI89 implies that
it acts on a regulatory network affecting type 1 piliation that is
conserved between K. pneumoniae and E. coli.
It is not clear why K. pneumoniae is programmed to keep
type 1 pili primarily in the phase-OFF orientation. While type
1 pili have been shown to be important in cystitis, perhaps the
presence of type 1 pili is detrimental for Klebsiella in other
environments or conditions. UPEC type 1 pili have been shown
to switch to a phase-OFF state in the kidney (56). Klebsiella
may have evolved to be primarily a kidney pathogen without
the need for high levels of type 1 pili in this niche. Type 1 pili
may be antigenic in the lung or gut and may lead to K. pneu-
moniae clearance. Additionally, while capsule is an essential
virulence factor for K. pneumoniae in many environments (2),
it has also been shown to impede adhesion to and invasion of
bladder epithelial cells (55). It has been noted that type 1 pili
and capsule may be inversely expressed or regulated in K.
pneumoniae (40), and this may explain the predisposition to-
ward a less-piliated state.
Our studies have demonstrated that the ability to utilize an
intracellular niche during UTI is not specific to UPEC alone.
Despite being able to progress through an IBC pathway, K.
pneumoniae forms fewer IBCs and has lower titers in bladder
than UPEC early in infection. These differences are related, in
part, to type 1 pilus expression. This work begins to explain the
difference in prevalence of E. coli and K. pneumoniae UTIs and
emphasizes the importance of type 1 pilus regulatory elements
in the ability of uropathogens to infect the urinary tract.
Specifically, we have identified a novel regulatory gene in K.
pneumoniae, fimK, capable of suppressing IBC and biofilm
formation and impeding UTI pathogenesis.
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